LY6G6D Recombinant Antibody
| Genentech’s innovative anti-LY6G6D/CD3 bispecific antibody (LY6G6D-TDB) demonstrates potent anti-tumor efficacy in colorectal cancer (CRC) models, both as a standalone treatment and in combination with PD-1 blockade. The most recent research findings have revealed that LY6G6D has emerged as a potential target for the treatment of colorectal cancer.
Read more：LY6G6D (LY6-G): A New Member of Lymphocyte Antigen-6 Family Holds Big Opportunities in Bispecific Antibody for CRC Treatment! CUSABIO has successfully developed the recombinant antibody specifically targeting human LY6G6D, demonstrating excellent binding activity with both recombinant human LY6G6D protein and recombinant monkey LY6G6D protein. |
| Code: CSB-RA013246MA2HU
Species Reactivity: Human, Mouse, Rat, Macaca fascicularis |
